Kontakta oss

Vänligen fyll i formuläret nedan, så återkommer vi så snart som möjligt.
*
*
KONTAKTA MIG VIA
 
Copyright © 2004- Genomic Health, Inc., ett Exact Sciences-företag. Alla rättigheter förbehålls.
I USA och vissa andra jurisdiktioner är Genomic Health, Oncotype DX, Oncotype IQ, Recurrence Score och Oncotype DX Breast Recurrence Score registrerade varumärken. ”Making cancer care smarter” och GPS är registrerade varumärken som tillhör Genomic Health, Inc., ett Exact Sciences-företag.


REFERENSER

  1. JA Sparano, R J Gray, DF. Makower, et al. Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. 2018, N Engl J Med, Vol. 379, pp. 111-121.
  2. Kalinsky K, Barlow WE, Meric-Bernstam F, et al. First results from a phase III randomized clinical trial of standard adjuvant endocrine therapy +/- chemotherapy in patients with 13 positive nodes, hormone receptor-positive and HER2-negative breast cancer with Recurrence Score ?25: SWOG S1007 (RxPONDER). SABCS: s.n., 2020. GS3-00.
  3. Paik S, Tang, G, & Shak S et al. Gene expression and benefit of chemotherapy in women with node-negative disease, estrogen recpetor -postive breast cancer. 23, 2006, Journal of Clinical Oncology, Vol. 24, pp. 3726-3734.
  4. Albain KS, Barlow WE, Shak s, et al. Prognostic and predictive value of the 21-gene recurrence socre assay in postmenopausal women with node-positive, osetorgen-receptor-positive breast cancer on chemotherapy: a retropsective analysis of a randomised trial. 2009, The Lancet Oncology, Vol. 11, pp. 55-65.
  5. NCCN Guidelines Insights: Breast Cancer, Version 3.2021.
  6. IQWiG Press Releases, September 2018. Available at: https://www.iqwig.de/en/press/press-releases/biomarker-tests-in-breast-cancer-new-study-data-indicate-advantage-for-certain-patients.10059.html. IQWiG Press Release 2020. Available at: https://www.iqwig.de/en/press/press-releases/biomarker-tests-for-decision-making-on-chemotherapy-for-breast-cancer-no-evidence-of-transferability.12882.html
  7. NICE 2018. Available at: https://www.nice.org.uk/guidance/ng101/chapter/Recommendations
  8. Burstein et al. Ann Oncol. 2021.
  9. Andre et al. J Clin Oncol. 2019.
  10. Cardoso et al. Ann Oncol. 2019.
  11. IQWiG Press Release, Addendum D18-0. 2018.
  12. Tandvårds- och läkemedelsförmånsverket, Health economic assessment of Oncotype DX in breast cancer. TLV.SE. [Online] https://www.tlv.se/medicinteknik/halsoekonomiska-bedomningar/avslutade-bedomningar/arkiv/2021-07-12-halsoekonomisk-bedomning-av-oncotype-dx-vid-brostcancer.html. [Cited: July 12th, 2021.] https://www.tlv.se/medicinteknik/halsoekonomiska-bedomningar/avslutade-bedomningar/arkiv/2021-07-12-halsoekonomisk-bedomning-av-oncotype-dx-vid-brostcancer.html.
  13. Sparano et al. N Engl J Med. 2015.
  14. Sparano et al. N Engl J Med. 2018.


Making cancer care smarter.™